Table 2 Characteristics of the included randomized controlled trials.
Author | Year | Country | Sample size | Age (mean) | Anaesthesia | Intervention | |||
|---|---|---|---|---|---|---|---|---|---|
ACB | FNB | ACB | FNB | ACB | FNB | ||||
Elkassabany et al. | 2016 | USA | 31 | 31 | 63 | 65 | General/Spinal | 20 ml Ropivacaine 0.5% + LIF | 20 ml Ropivacaine 0.5% + LIF |
Wiesmann et al. | 2016 | Germany | 21 | 21 | 72 | 66 | General | Ropivacaine 0.2% + ASNB | Ropivacaine 0.2% + ASNB |
Zhang et al. | 2015 | China | 30 | 30 | 65 | 64 | General | 20 ml Ropivacaine 0.3% | 20 ml Ropivacaine 0.3% |
Tan et al. | 2015 | China | 40 | 40 | 65 | 63 | General | 20 ml Ropivacaine 5 g/L, 20 ml + 0.1 mg Epinephrine + LIF | 30 ml Ropivacaine 3.33 g/L + 0.1 mg Epinephrine + LIF |
Memtsoudis et al. | 2015 | USA | 30 | 29 | 64 | 64 | Spinal epidural | 15 ml bupivacaine 0.25% | 30 ml bupivacaine 0.25% |
Machi et al. | 2015 | USA | 39 | 41 | 67 | 66 | General/Spinal | Ropivacaine 0.2% | Ropivacaine 0.2% |
Grevstad et al. | 2015 | Denmark | 25 | 24 | 65 | 64 | Spinal | Ropivacaine 0.2% | Ropivacaine 0.2% |
Zhang et al. | 2014 | China | 30 | 30 | 64 | 62 | Spinal epidural | 20 ml Ropivacaine 0.33% | 20 ml Ropivacaine 0.33% |
Shah et al. | 2014 | India | 48 | 50 | 68 | 66 | Spinal | 20 ml Ropivacaine 0.75% + LIF | 30 cc. Ropivacaine 0.75% + LIF |
Liu et al. | 2014 | China | 19 | 19 | 61 | 63 | General | 20 ml Ropivacaine 0.5% + LIF | 30 ml Ropivacaine 0.33% + LIF |
Kim et al. | 2014 | USA | 46 | 47 | 68 | 68 | Spinal epidural | 15 cc Bupivacaine 0.5% + 5 μg/ml Epinephrine | 30 cc Bupivacaine 0.25% + 5 μg/ml Epinephrine |
Jaeger et al. | 2013 | Denmark | 22 | 26 | 70 | 66 | Spinal | 30 ml Ropivacaine 0.5% + 192 ml 0.2% Ropivacaine infusion | 30 ml Ropivacaine 0.5% + 192 ml 0.2% Ropivacaine infusion |
